Iterum Therapeutics Plc Return on Equity

Iterum Therapeutics Plc (ITRM) currently reports a ROE of 365.28%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Iterum Therapeutics Plc's ROE history and peer comparisons.

Iterum Therapeutics Plc's ROE of 365.28% is higher than the Healthcare sector average of 11.15%. That is roughly 3174.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Iterum Therapeutics Plc's current 365.28% should be judged against Healthcare norms (sector average: 11.15%) and against ITRM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 365.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Iterum Therapeutics Plc, and consider following ITRM for alerts when major investors trade the stock.

Iterum Therapeutics Plc is classified in the Healthcare sector. On ROE, it currently shows 365.28% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ITRM with unrelated industries.